Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Opus Genetics (IRD) FCF Margin (2020 - 2026)

Opus Genetics has reported FCF Margin over the past 7 years, most recently at 590.03% for Q1 2026.

  • Quarterly FCF Margin fell 38422.0% to 590.03% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 325.34% through Mar 2026, down 11398.0% year-over-year, with the annual reading at 248.33% for FY2025, 1565.0% down from the prior year.
  • FCF Margin was 590.03% for Q1 2026 at Opus Genetics, down from 254.41% in the prior quarter.
  • Over five years, FCF Margin peaked at 268.95% in Q4 2023 and troughed at 655.76% in Q2 2024.
  • The 5-year median for FCF Margin is 202.89% (2025), against an average of 197.67%.
  • Year-over-year, FCF Margin crashed -68267bps in 2024 and then soared 29944bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 72.25% in 2022, then surged by 272bps to 268.95% in 2023, then plummeted by -164bps to 172.9% in 2024, then tumbled by -47bps to 254.41% in 2025, then plummeted by -132bps to 590.03% in 2026.
  • Per Business Quant, the three most recent readings for IRD's FCF Margin are 590.03% (Q1 2026), 254.41% (Q4 2025), and 199.97% (Q3 2025).